We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Purpose-Built COVID-19 LIMS Solution Jump-Starts COVID-19 Testing and Research

By LabMedica International staff writers
Posted on 11 May 2020
A new purpose-built COVID-19 laboratory information management system (LIMS) solution can jump-start the ability of laboratories everywhere to enter biospecimens into a biobank and rapidly begin conducting COVID-19-related testing and research.

The new COVID-19 Biobanking Accelerator is built on the LabVantage Solutions, Inc.’s (Somerset, NJ, USA) industry-leading LIMS and Biobanking platforms used by clinical laboratories around the globe. More...
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment. Being pre-configured means minimal implementation time is needed with a go-live start possible in less than four weeks.

The LIMS Accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. It incorporates multiple protocols defined by the CDC for COVID-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification and serology.

“Widespread laboratory testing is a critical component in the battle to control the coronavirus pandemic sweeping the globe. At LabVantage, we mobilized our decades of expertise to rapidly deliver a new purpose-built Biobanking LIMS to support COVID-19 testing and research,” said LabVantage CEO John Heiser. “It incorporates our deep knowledge of biobanking along with numerous features designed to make it easy for laboratories to acquire, implement and use the most powerful LIMS on the market for their COVID-19 testing. The LIMS Accelerator is also scalable, an important attribute as testing volumes escalate. Our outstanding service team stands ready to help customers begin using the package almost immediately. We are honored to have the opportunity to contribute to the laboratory testing and research that is critical to controlling and ultimately eliminating this devastating pandemic.”

Related Links:
LabVantage Solutions, Inc.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.